je.st
news
Tag: merck
Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection
2013-09-23 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application for sugammadex sodium injection, Mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. Language: English Contact: Media:Pam Eisele, 908-423-5042orSarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: complete
response
letter
medicine
Merck Named To 2013 Working Mother 100 Best Companies
2013-09-17 20:20:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has been named as one of the Working Mother 100 Best Companies for 2013. Honored on the list for the 26th year, Merck is among the 100 companies recognized for their commitment to progressive workplace programs, including female representation, compensation, child care, flexibility, time off and leave, family-friendly programs and company culture. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: working
companies
mother
named
Merck, AstraZeneca reach deal on cancer treatment
2013-09-11 16:51:46| Biotech - Topix.net
AstraZeneca PLC will take over clinical development of a potential ovarian cancer treatment from Merck & Co.
Tags: treatment
deal
reach
cancer
Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer
2013-09-11 09:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & LONDON WHITEHOUSE STATION, N.J. & LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Mercks oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer. Language: English Contact: MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
enter
agreement
license
Merck Animal Health Introduces Next Generation of Circovirus Protection
2013-09-11 02:00:00| ThePigSite - Industry News
US - Merck Animal Health is offering the first porcine circovirus Type 2 (PCV2) vaccine - Circumvent® PCV G2 - for use in pigs as early as three days of age.
Tags: health
protection
generation
animal
Sites : [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] next »